| NCT ID | NCT05772845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Acute Abstinence From Cigarettes vs E-cigarettes (ENDS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 370 participants |
| Start Date | 2023-02-14 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 370 participants in total. It began in 2023-02-14 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed research, which will systematically and comprehensively characterize the withdrawal among daily vapers compared to daily smokers of combustible cigarettes, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence/abuse liability and contributing to the development of therapies for tobacco/nicotine use, the leading preventable cause of death in the US.
Eligibility Criteria
Inclusion Criteria: * 6+ months of daily/near-daily nicotine vaping and/or cigarette smoking (to yield 160 vapers, 160 smokers, 50 dual users) * 200+ ng/mL cotinine on a commercially-available quick screen Current Exclusion Criteria: * intention to quit daily/near-daily vaping/smoking in the next month * current (2+ days out of the past 7) use of pipe tobacco, hookah/shisha, smokeless tobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+ days out of past 7) use of cigars, cigarillos, or filtered cigars that are filled with tobacco or a mix of tobacco and marijuana * current use of any smoking cessation medication * current severe substance dependence other than tobacco/nicotine (including cannabis; NIDA Modified ASSIST of 27+) * current (past 2 weeks) suicidal ideation with intent and/or plan * current antipsychotic medications or lifetime history of schizophrenia or bipolar disorder * pregnancy (intake urine screen) Original Exclusion Criteria that have been modified or eliminated: * \>1 use in past month of tobacco/nicotine products other than ENDS and combustible cigarettes (modified 5/19/25 - see current exclusion criteria) * alcohol: AUDIT \> 15 for males and \>13 for females (eliminated 7/25/23) * current major depression (PHQ-9\>11) (eliminated 7/25/23) * suicide risk (answer to question #9 on PHQ-9 is anything other than "Not at all") (modified 11/17/23 - see current exclusion criteria)
Contact & Investigator
Larry Hawk, PhD
PRINCIPAL INVESTIGATOR
University at Buffalo
Frequently Asked Questions
Who can join the NCT05772845 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 50 Years, studying Acute Abstinence From Cigarettes vs E-cigarettes (ENDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05772845 currently recruiting?
Yes, NCT05772845 is actively recruiting participants. Contact the research team at lhawk@buffalo.edu for enrollment information.
Where is the NCT05772845 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT05772845 clinical trial?
NCT05772845 is sponsored by State University of New York at Buffalo. The principal investigator is Larry Hawk, PhD at University at Buffalo. The trial plans to enroll 370 participants.